El uso de la corifolitropina alfa en donantes de óvulos obtiene la misma eficiencia reproductiva y efectividad que la FSH recombinante, con una mayor comodidad para la donante

Abstract

IntroductionConventional ovarian stimulation with daily injections of FSH for oocyte donors, besides the discomfort of the medication, involves a great demand of time. Treatments need to be simplified without losing effectiveness and safety. Corifollitropin alpha (Elonva) enables the first 7injections of FSH to be replaced with one single injection. ObjectiveTo compare the effectiveness and convenience of corifollitropin alpha (Elonva) compared to daily recombinant FSH (rFSH) in the ovarian stimulation of oocyte donors. Materials and methodsAn analysis was performed on 90 cycles of Elonva and 96 cycles of rFSH. The statistical analysis included the Student t-test for means and the chi-squared test for percentages. Effectiveness has been evaluated through reproductive effectiveness defined as the total number of live births in relation to the total number of mature eggs. An analysis was also performed on variables, such as number of mature oocytes, percentage of viable embryos, implantation rate, and clinical pregnancy rate per embryo transfer. Comfort has been evaluated by the number of visits to the clinic for medication administration. ResultsSignificant differences were only found in the number of injections administered to donors (3.20 Elonva vs. 8.55 rFSH, P<.005). Reproductive effectiveness was 5.61 vs. 5.49, with implantation rate 44.44 vs. 44.34, and clinical pregnancy 56.25 vs. 58.73. There no significant differences in any of variables analysed, including the mean cost. No cases of OHSS or adverse drug reactions were observed. ConclusionsThe use of corifollitropin alpha in oocyte donors offers the same reproductive effectiveness and is more convenient for the donor compared to stimulation with daily rFSH.